Medicinal Chemistry Research

, Volume 26, Issue 12, pp 3158–3172 | Cite as

Design and synthesis of novel 2-(5-(4-aryl)-4,5-dihydro-1H-pyrazol-3-yl)-1-(substituted aminomethyl)-1H-benzimidazole as potent anticonvulsants

  • Pullagura Mallikarjuna Krishna Prasad
  • Raja Sundararajan
Original Research


A variety of novel 2-(5-(4-aryl)-4,5-dihydro-1H-pyrazol-3-yl)-1-(substitutedaminomethyl)-1H-benzimidazole 5a5l have been synthesized from o-phenylenediamine by a multi-step synthesis. Antiepileptic screening of the title compounds was performed using maximal electroshock and subcutaneous pentylenetetrazole seizures tests while the neurotoxicity was determined by rotorod test. In the preliminary screening, compounds 5d, 5e, 5f and 5l were found active in maximal electroshock model; while 5d, 5e, 5f and 5k showed significant antiepileptic activity in subcutaneous pentylenetetrazole seizure model. Further all these five compounds were administered to rats at 30 mg/kg dose in oral route and found that compounds 5e and 5f showed better activity than Phenytoin. These compounds 5e and 5f revealed protection in maximal electroshock after intraperitoneal administration at a dose of 30 mg/kg (0.5 h and 4.0 h). These compounds also provided protection in the subcutaneous pentylenetetrazole seizure at a dose of 100 mg/kg (0.5 h) and 300 mg/kg (4 h).


Benzimidazole Pyrazole Epilepsy In vivo studies Neurotoxicity 



The authors gratefully acknowledge the Pfizer limited and GITAM University for providing infrastructure facilities to carry out this research work.

Compliance with ethical standards

Conflict of interests

The authors declares that they have no competing interests.

Supplementary material

44_2017_2010_MOESM1_ESM.pdf (4.7 mb)
Supplementary Information


  1. Akhtar W, Khan MF, Verma G, Shaquiquzzaman M, Rizvi MA, Mehdi SH, Akhter M, Alam MM (2017) Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. Eur J Med Chem 126:705–753CrossRefPubMedGoogle Scholar
  2. Alagarsamy V, Saravanan G (2012) Synthesis and anticonvulsant activity of novel quinazolin-4(3H)-one derived pyrazole analogs. Med Chem Res 22:1711–1722CrossRefGoogle Scholar
  3. Alam O, Mullick P, Verma SP, Gilani SJ, Khan SA, Siddiqui N, Ahsan W (2010) Synthesis, anticonvulsant and toxicity screening of newer pyrimidine semicarbazone derivatives. Eur J Med Chem 45:2467–2472CrossRefPubMedGoogle Scholar
  4. Berk M, Segal J, Janet L, Vorster M (2001) Emerging options in the treatment of bipolar disorders. Drugs 61:1407–1414CrossRefPubMedGoogle Scholar
  5. Bhrigu B, Siddiqui N, Pathak D, Alam MS, Ali R, Azad B (2012) Anticonvulsant evaluation of some newer benzimidazole derivatives: design and synthesis. Acta Pol Pharm 69:53–62PubMedGoogle Scholar
  6. Bindi S, Fancelli D, Alli C, Berta D, Bertrand JA, Cameron AD, Cappella P, Carpinelli P, Cervi G, Croci V, D’anello M, Forte B, Giorgini M, Marsiglio A, Moll J, Pesenti E, Pittala V, Pulici M, Riccardi-Sirtori F, Roletto F, Soncini C, Storici P, Varasi M, Volpi D, Zugnoni P, Vianello P (2010) Thieno[3,2-c]pyrazoles: a novel class of aurora inhibitors with favorable antitumor activity. Bioorg Med Chem 18:7113–7120CrossRefPubMedGoogle Scholar
  7. Bruno-Blanch L, Galvez J, Garcia-Domenach R (2003) Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity. Bioorg Med Chem Lett 13:2749–2754CrossRefPubMedGoogle Scholar
  8. Castro AR, Rivera IL, Rojas LC, Vazquez GN, Rodríguez AN (2011) Synthesis and preliminary evaluation of selected 2-aryl-5 (6)-nitro-1H-benzimidazole derivatives as potential anticancer agents. Arch Pharm Res 34:181–189CrossRefGoogle Scholar
  9. Deng XQ, Wei CX, Li FN, Sun ZG, Quan ZS (2010) Design and synthesis of 10-alkoxy-5,6-dihydro-triazolo-[4,3-d]benzo-[f]-[1,4]oxazepine derivatives with anticonvulsant activity. Eur J Med Chem 45:3080–3086CrossRefPubMedGoogle Scholar
  10. Duncan JS (2002) The promise of new antiepileptic drugs. Br J Clin Pharmacol 53:123–131CrossRefPubMedPubMedCentralGoogle Scholar
  11. Dunham MS, Miya TA (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Sci 46:208–209CrossRefGoogle Scholar
  12. Estrada E, Pena A (2000) In silico studies for the rational discovery of anticonvulsant compounds. Bioorg Med Chem 8:2755–2770CrossRefPubMedGoogle Scholar
  13. Jun C, Jiangtao X, Xianjin L (2005) Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives. Bioorg Med Chem Lett 15:267–269CrossRefGoogle Scholar
  14. Karakurt A, Ozalp M, Isik S, Stables JP, Dalkara S (2010) Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives. Bioorg Med Chem 8:2902–2911CrossRefGoogle Scholar
  15. Kaur G, Kaur M, Silakari O (2014) Benzimidazoles: An ideal privileged drug scaffold for the design of multitargeted anti-inflammatory ligands. Mini Rev Med Chem 14:747–767CrossRefPubMedGoogle Scholar
  16. Lopes Lima JM (2000) The new drugs and the strategies to manage epilepsy. Curr Pharm Des 6:873–878CrossRefGoogle Scholar
  17. McNamara JO (2001) Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Gilman AG (Eds.) The pharmacological basis of therapeutics. McGraw-Hill, New York, NY, p 521–548Google Scholar
  18. Monika G, Chander M (2015) Design, synthesis and biological evaluation of novel 1,2,5-substituted benzimidazole derivatives as gastroprotective anti-inflammatory and analgesic agents. Med Chem 5:58–63Google Scholar
  19. Olfert ED, Cross BM, McWilliam AA (1993) Guide to the care and use of experimental animals, Vol 1, 2nd edn. Canadian council of animal care, Canada, p 1–201Google Scholar
  20. Panneer Selvam T, Vijayaraj Kumar P, Saravanan G, Prakash CR (2014) Microwave-assisted synthesis, characterization and biological activity of novel pyrazole derivatives. J Saudi Chem Soc 18:1015–1021CrossRefGoogle Scholar
  21. Pevarello P, Fancelli D, Vulpetti A, Amici R, Villa M, Pittala V, Vianello P, Cameron A, Ciomei M, Mercurio C, Bischoff J, Roletto F, Varasi M, Brasca MG (2006) 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors. Bioorg Med Chem Lett 16:1084–1090CrossRefPubMedGoogle Scholar
  22. Pollard JR, French J (2006) Antiepileptic drugs in development. Lancet Neurol 5:1064–1067CrossRefPubMedGoogle Scholar
  23. Rajak H, Deshmukh R, Aggarwal N, Kashaw S, Kharya MD, Mishra P (2009) Synthesis of novel 2,5-disubstituted-1,3,4-thiadiazoles for their potential anticonvulsant activity: pharmacophoric model studies. Arch Pharm 342:453–461CrossRefGoogle Scholar
  24. Salerno L, Modica MN, Romeo G, Pittala V, Siracusa MA, Amato ME, Acquaviva R, Di Giacomo C, Sorrenti V (2012) Novel inhibitors of nitric oxide synthase with antioxidant properties. Eur J Med Chem 49:118–126CrossRefPubMedGoogle Scholar
  25. Siddiqui N, Alam MS, Ali R, Yar SM, Alam O (2016) Synthesis of new benzimidazole and phenylhydrazinecarbothiomide hybrids and their anticonvulsant activity. Med Chem Res 25:1390–1402CrossRefGoogle Scholar
  26. Siracusa MA, Salerno L, Modica MN, Pittala V, Romeo G, Amato ME, Nowak M, Bojarski AJ, Mereghetti I, Cagnotto A, Mennini T (2008) Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands. J Med Chem 51:4529–4538CrossRefPubMedGoogle Scholar
  27. Spear BB (2001) Pharmacogenetics and antiepileptic drug. Epilepsia 42:31–34CrossRefPubMedGoogle Scholar
  28. Sri Krishnanjaneyulu I, Saravanan G, Vamsi J, Supriya P, Udaya Bhavana J, Venkata Sunil Kumar M (2014) Synthesis, characterization and antimicrobial activity of some novel benzimidazole derivatives. J Adv Pharm Technol Res 5:21–27CrossRefGoogle Scholar
  29. Stefan H, Feuerstein TJ (2007) Novel anticonvulsant drugs. Pharmacol Ther 113:165–183CrossRefPubMedGoogle Scholar
  30. Swinyard EA, Clark LD, Miyahara JT, Wolf HH (1961) Studies on the mechanism of amphetamine toxicity in aggregated mice. J Physiol 132:97–102Google Scholar
  31. Swiqtkiewicz KB, Olasik EM (2015) Some characteristics of activity of potential chemotherapeutics-benzimidazole derivatives. Adv Med Sci 60:125–132CrossRefGoogle Scholar
  32. White HS, Johnson M, Wolf HH, Kupferberg HJ (1995) The early identification of anticonvulsant activity: the role of maximal electroshock and subcutaneous pentylenetetrazole seizure models. Ital J Neurol Sci 16:73–77CrossRefPubMedGoogle Scholar
  33. Woodbury LA, Davenport VD (1952) Design and use of a new electroshock apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn Ther 92:97–107PubMedGoogle Scholar
  34. Yogeeswari P, Sriram D, Ragavendran JV, Thirumurugan R (2005) The GABA shunt: an attractive and potential therapeutic target in the treatment of epileptic disorders. Curr Drug Metab 6:127–139CrossRefPubMedGoogle Scholar
  35. Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran JV, Sudhan K, Pavana RK, Stables JP (2005) Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore based design. J Med Chem 48:6202–6211CrossRefPubMedGoogle Scholar
  36. Yoon YK, Ali MS, Wei AC, Choon TS, Ismail R (2015) Synthesis and evaluation of antimycobacterial activity of new benzimidazole aminoesters. Eur J Med Chem 93:614–624CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Pullagura Mallikarjuna Krishna Prasad
    • 1
  • Raja Sundararajan
    • 2
  1. 1.Pfizer LimitedPfizer CenterMumbaiIndia
  2. 2.Department of Pharmaceutical Chemistry, GITAM Institute of PharmacyGITAM UniversityVisakhapatnamIndia

Personalised recommendations